JP2024539655A5 - - Google Patents

Info

Publication number
JP2024539655A5
JP2024539655A5 JP2024522548A JP2024522548A JP2024539655A5 JP 2024539655 A5 JP2024539655 A5 JP 2024539655A5 JP 2024522548 A JP2024522548 A JP 2024522548A JP 2024522548 A JP2024522548 A JP 2024522548A JP 2024539655 A5 JP2024539655 A5 JP 2024539655A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
hydrogen
unsubstituted alkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539655A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/046386 external-priority patent/WO2023064343A1/en
Publication of JP2024539655A publication Critical patent/JP2024539655A/ja
Publication of JP2024539655A5 publication Critical patent/JP2024539655A5/ja
Pending legal-status Critical Current

Links

JP2024522548A 2021-10-13 2022-10-12 グルコセレブロシダーゼ活性の小分子モジュレーターおよびその使用 Pending JP2024539655A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163255272P 2021-10-13 2021-10-13
US63/255,272 2021-10-13
PCT/US2022/046386 WO2023064343A1 (en) 2021-10-13 2022-10-12 Small molecule modulators of glucocerebrosidase activity and uses thereof

Publications (2)

Publication Number Publication Date
JP2024539655A JP2024539655A (ja) 2024-10-29
JP2024539655A5 true JP2024539655A5 (enExample) 2025-10-20

Family

ID=85988704

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522548A Pending JP2024539655A (ja) 2021-10-13 2022-10-12 グルコセレブロシダーゼ活性の小分子モジュレーターおよびその使用

Country Status (15)

Country Link
US (1) US20250034170A1 (enExample)
EP (1) EP4415706A4 (enExample)
JP (1) JP2024539655A (enExample)
KR (1) KR20240102969A (enExample)
CN (1) CN118382436A (enExample)
AR (1) AR127355A1 (enExample)
AU (1) AU2022364718A1 (enExample)
CA (1) CA3235270A1 (enExample)
CL (1) CL2024001109A1 (enExample)
IL (1) IL312086A (enExample)
JO (1) JOP20240081A1 (enExample)
MX (1) MX2024004581A (enExample)
PE (1) PE20242105A1 (enExample)
TW (1) TW202327586A (enExample)
WO (1) WO2023064343A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024355840A1 (en) * 2023-10-04 2026-03-19 The Board Of Trustees Of The University Of Illinois Fused heterocycles for treating neurodegenerative diseases
CN117659014A (zh) * 2023-12-05 2024-03-08 上海药坦药物研究开发有限公司 5,5-二氟-2,7-二氮杂螺[3.5]壬烷类化合物及其制备方法
WO2025237303A1 (zh) * 2024-05-14 2025-11-20 先声药业有限公司 β-葡萄糖脑苷脂酶变构调节剂、其药物组合物及用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302811D0 (sv) * 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
DE102005030051A1 (de) * 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
GB0601402D0 (en) * 2006-01-24 2006-03-08 Syngenta Participations Ag Chemical Compounds
AR062841A1 (es) * 2006-09-15 2008-12-10 Schering Corp Tratamiento del dolor, diabetes, y trastornos del metabolismo de los lipidos
TW201026708A (en) * 2008-12-12 2010-07-16 Solvay Pharm Bv Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
WO2012009217A1 (en) * 2010-07-13 2012-01-19 Merck Sharp & Dohme Corp. Spirocyclic compounds
PL3366688T3 (pl) * 2010-12-08 2022-05-23 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy
US8828996B2 (en) * 2011-03-14 2014-09-09 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
JP2017502961A (ja) * 2013-12-23 2017-01-26 アレクトス セラピューティックス インコーポレイテッド グルコセレブロシダーゼモジュレーターおよびその使用
CN108290855A (zh) * 2015-07-01 2018-07-17 西北大学 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途
EP3661919A4 (en) * 2017-08-02 2021-03-31 Northwestern University SUBSTITUTED FUSION PYRIMIDINE COMPOUNDS AND THEIR USES
ES2937039T3 (es) * 2017-11-03 2023-03-23 Bristol Myers Squibb Co Inhibidores diazaespiro de ROCK
US10882865B2 (en) * 2018-08-31 2021-01-05 Northwestern University Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity
CA3218259A1 (en) * 2021-04-30 2022-11-03 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof

Similar Documents

Publication Publication Date Title
JP2008513498A5 (enExample)
JP6938561B2 (ja) 重水素化２，４−チアゾリジンジオン及び治療方法
EP2046775B1 (fr) Derives de n- (amino-heteroaryl) - 1h-indole-2 -carboxamides comme antagonistes des recepteurs de type trpv1 ou vr1
JP5715340B2 (ja) Ｎａｄｐｈオキシダーゼインヒビターとしてのピラゾロピリジン誘導体
JP2021534124A5 (enExample)
JP2008513506A5 (enExample)
JP2008513516A5 (enExample)
JP2011526926A5 (enExample)
CA3157798A1 (en) 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity
RU2006105717A (ru) Производные пиперазина и их применение в качестве терапевтических агентов
WO2000012487A1 (en) Pyrimidine derivatives
JP2008513496A5 (enExample)
JP2011520792A5 (enExample)
CN103012378A (zh) 作为5-ht2a血清素受体调节剂适用于治疗与其相关的病症的3-苯基-吡唑衍生物
JP2008513504A5 (enExample)
US20160000783A1 (en) Trk-INHIBITING COMPOUND
CA2658799A1 (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
WO2004083167A1 (ja) スルファミド誘導体及びその医薬組成物
WO1998029397A1 (en) Fused pyrimidine compounds and medicinal use thereof
US20190389865A1 (en) SUBSTITUTED PYRROLO[1,2-a]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
JP2011517443A5 (enExample)
US10308647B2 (en) Fused imidazole derivatives as IDO/TDO inhibitors
CA2615611A1 (en) Indazole derivatives
JP2009502770A5 (enExample)
US20120058085A1 (en) Deuterium Modified Benzimidazoles